Natalia Blanco
Company: Morphic Therapeutics
Job title: Associate Director - Immuno-Oncology Biology
Seminars:
Discussion Panel: Debating the Promise of Combinational Strategies with TGF-β 1:00 pm
day: Day Two
Integrin αvβ8 Inhibitor Improves Immune Checkpoint Therapy in Tumor Models: Illuminating Monitoring Activity in the Blood 9:30 am
Immune-checkpoint blockade (ICB) is enhanced when combined with therapies that target tumor tolerance in refractory tumors Targeting αvβ8-mediated TGF-β 1/3 pathway enhances sensitivity to checkpoint therapies in tumor models Protein or transcriptomic assessment of granzyme B may provide a useful biomarker of response to a combination of ICB and αvβ8 inhibitorsRead more
day: Day Two